217 related articles for article (PubMed ID: 31101781)
1. [EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN PATIENTS WITH HCV 1B GENOTYPE INFECTION: REAL WORLD DATA].
Zhyvytsia D; Tsarova O; Skorokhodova N
Georgian Med News; 2019 Mar; (288):77-81. PubMed ID: 31101781
[TBL] [Abstract][Full Text] [Related]
2. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
3. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
[TBL] [Abstract][Full Text] [Related]
4. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
[TBL] [Abstract][Full Text] [Related]
5. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
[TBL] [Abstract][Full Text] [Related]
6. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
[TBL] [Abstract][Full Text] [Related]
7. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
[TBL] [Abstract][Full Text] [Related]
8. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ;
Int J Drug Policy; 2018 Dec; 62():94-103. PubMed ID: 30384028
[TBL] [Abstract][Full Text] [Related]
9. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
10. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
11. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
[TBL] [Abstract][Full Text] [Related]
12. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
[TBL] [Abstract][Full Text] [Related]
13. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Trifan A; Stanciu C; Gheorghe L; Iacob S; Curescu M; Cijevschi Prelipcean C; Stefanescu G; Girleanu I; Chiriac S; Mihai C; Brisc C; Goldis A; Sporea I; Miftode E; Bataga S; Rogoveanu I; Preda C; Caruntu FA; Singeap AM
Medicine (Baltimore); 2017 Dec; 96(50):e9271. PubMed ID: 29390377
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
[TBL] [Abstract][Full Text] [Related]
17. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
[TBL] [Abstract][Full Text] [Related]
18. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
Puigvehí M; De Cuenca B; Viu A; Diago M; Turnes J; Gea F; Pascasio JM; Lens S; Cabezas J; Badia E; Olveira A; Morillas RM; Torras X; Montoliu S; Cordero P; Castro JL; Salmerón J; Molina E; Sánchez-Ruano JJ; Moreno J; Antón MD; Moreno JM; De la Vega J; Calleja JL; Carrión JA
Liver Int; 2019 Jan; 39(1):90-97. PubMed ID: 30160363
[TBL] [Abstract][Full Text] [Related]
19. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Cheng EY; Saab S; Holt CD; Busuttil RW
Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
[TBL] [Abstract][Full Text] [Related]
20. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Forns X; Poordad F; Pedrosa M; Berenguer M; Wedemeyer H; Ferenci P; Shiffman ML; Fried MW; Lovell S; Trinh R; Lopez-Talavera JC; Everson G
Liver Int; 2015 Nov; 35(11):2358-62. PubMed ID: 26248955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
